
    
      This is a post-market medical device study. This study will compare best medical practice
      with or without adjunctive VNS Therapy in patients who are 16 years and older with
      pharmaco-resistant partial epilepsy. The Sponsor, Cyberonics, provides funding for this
      study. Patients are followed for 26 months, 24 of those months are following the initiation
      of treatment. No study sites will be permitted to enroll study subjects until Institutional
      Review Board (IRB)/Ethics Committee (EC) approval has been received.
    
  